Literature DB >> 2437951

Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level.

H S Cuckle, N J Wald, S G Thompson.   

Abstract

The risk of an individual woman having a pregnancy associated with Down's syndrome was estimated from her age and her serum alpha-fetoprotein (AFP) level at 14-20 weeks gestation. The estimates were made using published data on the risk of Down's syndrome in relation to maternal age from 4528 affected and over 5 million unaffected pregnancies, and on the risk in relation to serum AFP from 68 affected and 36,645 unaffected pregnancies. Separate estimates were derived for AFP levels using gestational age based on the time since the first day of the last menstrual period and on an ultrasound biparietal diameter measurement. In each case this was done with and without adjusting AFP levels to take account of maternal weight. The same sources of data were also used to construct six Down's syndrome screening policies, each combining information on maternal age and serum AFP. For example with one policy the detection rate would be 28% and would involve selecting 2.8% of unaffected pregnancies for amniocentesis; using age alone the same detection rate could only be achieved by selecting 4.3% of unaffected pregnancies for amniocentesis--an increase of 50%. In general, screening for Down's syndrome using both maternal age and serum AFP is more efficient than either alone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437951     DOI: 10.1111/j.1471-0528.1987.tb03115.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  70 in total

1.  Down's syndrome: the effects of prenatal diagnosis and demographic factors in a region of the eastern part of Germany.

Authors:  C Rösch; V Steinbicker; S Kropf
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a population-based study.

Authors:  Jeanette Falck Winther; John D Boice; John J Mulvihill; Marilyn Stovall; Kirsten Frederiksen; E Janet Tawn; Jorgen H Olsen
Journal:  Am J Hum Genet       Date:  2004-04-21       Impact factor: 11.025

3.  Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population.

Authors:  Francesco Padula; Pietro Cignini; Diana Giannarelli; Cristiana Brizzi; Claudio Coco; Laura D'Emidio; Elsa Giorgio; Maurizio Giorlandino; Lucia Mangiafico; Marialuisa Mastrandrea; Vincenzo Milite; Luisa Mobili; Cinzia Nanni; Raffaella Raffio; Cinzia Taramanni; Roberto Vigna; Alvaro Mesoraca; Domenico Bizzoco; Ivan Gabrielli; Gianluca Di Giacomo; Maria Antonietta Barone; Antonella Cima; Francesca Romana Giorlandino; Sabrina Emili; Marina Cupellaro; Claudio Giorlandino
Journal:  J Prenat Med       Date:  2014 Apr-Jun

4.  Increasing total prevalence rate of cases with Down syndrome in Hungary.

Authors:  Julia Métneki; Andrew E Czeizel
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

5.  Adaptive-filtering of trisomy 21: risk of Down syndrome depends on family size and age of previous child.

Authors:  Markus Neuhäuser; Sven Krackow
Journal:  Naturwissenschaften       Date:  2006-09-30

6.  Screening for Down's syndrome based on individual risk.

Authors:  M Lewis; M J Faed; P W Howie
Journal:  BMJ       Date:  1991-09-07

7.  A review of biochemical and ultrasound markers in the detection of down syndrome.

Authors:  Catherine C Peterson
Journal:  J Perinat Educ       Date:  2006

8.  Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21.

Authors:  K O Kagan; M Schmid; M Hoopmann; P Wagner; H Abele
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

9.  The ethics of antenatal screening: lessons from Canute.

Authors:  Timothy M Reynolds
Journal:  Clin Biochem Rev       Date:  2009-11

10.  Prenatal diagnosis for paediatricians.

Authors:  Anne Summers
Journal:  Paediatr Child Health       Date:  2003-01       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.